Alogliptin combinations filed for Japanese approval
This article was originally published in Scrip
Takeda has submitted marketing applications in Japan for its DPP-4 inhibitor alogliptin as a concomitant therapy with thiazolidinedione (TZD) antidiabetics, and also in a fixed-dose combination with its own TZD, pioglitazone.
You may also be interested in...
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context